Bruno Filoche-Rommé
Sanofi (France)(FR)
Publications by Year
Research Areas
Computational Drug Discovery Methods, Estrogen and related hormone effects, PI3K/AKT/mTOR signaling in cancer, Chronic Lymphocytic Leukemia Research, Advanced Breast Cancer Therapies
Most-Cited Works
- → A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy(2014)481 cited
- → Discovery of (2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one: A Novel Potent and Selective Inhibitor of Vps34 for the Treatment of Solid Tumors(2014)90 cited
- → Discovery and Optimization of Pyrimidone Indoline Amide PI3Kβ Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers(2014)84 cited
- → Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer(2019)81 cited
- → SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models(2020)66 cited
- → Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3Kβ Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers(2012)53 cited
- → SAR156497, an Exquisitely Selective Inhibitor of Aurora Kinases(2014)38 cited
- → Identification of β-Lactams Active against Mycobacterium tuberculosis by a Consortium of Pharmaceutical Companies and Academic Institutions(2022)24 cited
- → Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3Kβ inhibitors(2012)23 cited
- → Electrophysiological and Pharmacological Characterization of Human Inwardly Rectifying K ir 2.1 Channels on an Automated Patch-Clamp Platform(2019)21 cited